CVS, Express Scripts 2017 Formulary Exclusion Lists Make Waves

Go back to CVS, Express Scripts 2017 Formulary Exclusion Lists Make Waves

Biogen (BIIB) Peers on Watch Amid M&A Chatter (AMGN) (GILD)

August 2, 2016 2:52 PM EDT

Biogen (NASDAQ: BIIB) peers are on watch amid today's M&A chatter. Names include: Celgene (NASDAQ: CELG), Gilead Sciences (NASDAQ: GILD), and Amgen (NASDAQ: AMGN), among others.

... More

FBR Capital Remains Buyers of CVS Health (CVS) Following 'Solid' Quarter

August 2, 2016 2:16 PM EDT

FBR Capital analyst Steven Halper reiterated an Outperform rating and $120 price target on CVS Health (NYSE: CVS) following a 'solid' Q2. The firm remains buyers of the stock.

Halper commented, "On August 2, CVS reported strong 2Q16 results with the PBM segment performing slightly better... More

BMO Capital Positive on Horizon Pharma (HZNP) Amid CVS/Caremark News; Affirms at 'Outperform'

August 2, 2016 12:38 PM EDT

BMO Capital affirms Horizon Pharma (Nasdaq: HZNP) at Outperform with a price target of $29 after the company announced that two of its primary care products Duexis and Vimovo were removed from the 2017 CVS/Caremark exclusion list.

Analyst Gary Nachman commented today, We view this announcement as an important win for HZNP. It demonstrates that it is improving its execution on the managed care front as... More